Grady Chang

Grady Chang’s practice focuses on capital markets transactions and corporate, securities and governance matters. He represents investment banks and late-stage private and public companies in a variety of corporate and securities transactions, including initial public offerings, SPAC mergers, follow-on and secondary offerings, private placements and debt offerings.

Grady also counsels public companies with respect to general corporate and securities matters, including corporate governance, Exchange Act reporting obligations and stock exchange requirements.

Grady’s representative transactions include advising:

• Hyliion in its $516.5 million SPAC merger
• Canoo in its $607.1 million SPAC merger 
• WM Technology in its $579 million SPAC merger
• Xos in its $216.7 million SPAC merger
• The underwriters in FIGS’ $667.6 million IPO and follow-on offering
• The underwriters in Avidity Biosciences’ $289.1 million IPO and follow-on offering
• The underwriters in 4D Molecular Therapeutics’ $222.2 million IPO and follow-on offering
• The underwriters in 89bio’s $97.6 million IPO and follow-on offerings
• The underwriters in Angion Biomedica’s $92 million IPO
• The underwriters in Satsuma Pharmaceutical’s $82.5 million IPO

Prior to joining Cooley, Grady was a capital markets associate in the New York office of Simpson Thacher & Bartlett.